EFFICACY OF RUXOLITINIB IN MYELOID NEOPLASMS WITH PCM1-JAK2 FUSION GENE

被引：0
|
作者：
Casetti, I. C. [1 ]
Milosevic, J. D. [2 ]
Rumi, E. [3 ]
Selleslag, D. [4 ]
Lierman, E. [5 ]
Pietra, D. [3 ]
Cavalloni, C. [1 ]
Bellini, M. [1 ]
Milanesi, C. [3 ]
Astori, C. [3 ]
Kralovics, R. [2 ]
Vandenberghe, P. [5 ]
Cazzola, M. [1 ,3 ]
机构：
[1] IRCCS Policlin San Matteo, Dept Mol Med, Pavia, Italy
[2] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria
[3] IRCCS Policlin San Matteo, Dept Hematol Oncol, Pavia, Italy
[4] Acad Hosp St Jan, Dept Hematol, Brugge, Belgium
[5] Katholieke Univ Leuven, Univ Hosp Leuven, Ctr Human Genet, Leuven, Belgium
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1342
引用
收藏
页码：537 / 538
页数：2
相关论文
共 50 条
  • [31] PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation
    Murati, A
    Gelsi-Boyer, V
    Adélaïde, J
    Perot, C
    Talmant, P
    Giraudier, S
    Lodé, L
    Letessier, A
    Delaval, B
    Brunel, V
    Imbert, M
    Garand, R
    Xerri, L
    Birnbaum, D
    Mozziconacci, M
    Chaffanet, M
    LEUKEMIA, 2005, 19 (09) : 1692 - 1696
  • [32] A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphoma
    Adélaïde, J
    Pérot, C
    Gelsi-Boyer, V
    Pautas, C
    Murati, A
    Copie-Bergman, C
    Imbert, M
    Chaffanet, M
    Birnbaum, D
    Mozziconacci, MJ
    LEUKEMIA, 2006, 20 (03) : 536 - 537
  • [33] PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation
    A Murati
    V Gelsi-Boyer
    J Adélaïde
    C Perot
    P Talmant
    S Giraudier
    L Lodé
    A Letessier
    B Delaval
    V Brunel
    M Imbert
    R Garand
    L Xerri
    D Birnbaum
    M J Mozziconacci
    M Chaffanet
    Leukemia, 2005, 19 : 1692 - 1696
  • [34] MOLECULAR MONITORING OF PCM1-JAK2 FUSION TRANSCRIPT IN A CASE OF ATYPICAL CHRONIC MYELOID LEUKEMIA WITH T(8;9)(P22;24)
    Masselli, E.
    Prezioso, L.
    Mecucci, C.
    Sammarelli, G.
    Bonomini, S.
    Lambertini, C.
    Craviotto, L.
    Rossetti, E.
    Caramatti, C.
    Vitale, M.
    Aversa, F.
    HAEMATOLOGICA, 2014, 99 : 669 - 669
  • [35] Revisiting the WHO entity "myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2" in 74 patients: lack of eosinophilia and presence of monocytosis
    Steiner, L.
    Schwaab, J.
    Naumann, N.
    Jahwar, M.
    Kreil, S.
    Haferlach, T.
    Fabarius, A.
    Hofmann, W. -K.
    Cross, N. C. P.
    Reiter, A.
    Metzgeroth, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 80 - 80
  • [36] RUXOLITINIB AS POTENTIAL TARGETED THERAPY FOR MYELOPROLIFERATIVE NEOPLASMS WITH JAK2 FUSION PROTEINS
    Chase, A.
    Bryant, C.
    Score, J.
    Haferlach, C.
    Schwaab, J.
    Hofmann, W. K.
    Reiter, A.
    Cross, N.
    HAEMATOLOGICA, 2012, 97 : 436 - 436
  • [37] Myeloproliferative disorders carrying the t(8;9) (PCM1-JAK2) transtocation -: reply
    Tzankov, A
    Heiss, S
    HUMAN PATHOLOGY, 2006, 37 (04) : 500 - 502
  • [38] Hodgkin Lymphoma and Cutaneous T-Cell Lymphoma Sharing the PCM1-JAK2 Fusion and a Common T-Cell Clone
    Riedlinger, Gregory M.
    Chojecki, Aleksander
    Aviv, Hana
    Weissmann, David
    Joshi, Sonali
    Murphy, Susan M.
    Hirshfield, Kim M.
    Ganesan, Shridar
    JCO PRECISION ONCOLOGY, 2019, 3 : 1 - 8
  • [39] Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis
    Mesa, Ruben A.
    IDRUGS, 2010, 13 (06) : 394 - 403
  • [40] PCM1-JAK2 Fusion Product Selectively Activates MAP-Kinase Pathway and Fails to Phosphorylate JAK2 and STAT5: Implications for Therapeutic Strategies.
    Masselli, Elena
    Mecucci, Cristina
    Gobbi, Giuliana
    Carubbi, Cecilia
    Bonomini, Sabrina
    Prezioso, Lucia
    Rossetti, Elena
    Caramatti, Cecilia
    Vitale, Marco
    Aversa, Franco
    BLOOD, 2012, 120 (21)
12345